MIP-1095 is an inhibitor of the prostate-specific membrane antigen (PSMA). References: Robertson N, Rappas M, Doré AS, Brown J, Bottegoni G, Koglin M, Cansfield J, Jazayeri A, Cooke RM, Marshall FH. Structure of the complement C5a receptor bound to the extra-helical antagonist NDT9513727. Nature. 2018 Jan 3;553(7686):111-114. doi: 10.1038/nature25025. PubMed PMID: 29300009. 2: Brodbeck RM, Cortright DN, Kieltyka AP, Yu J, Baltazar CO, Buck ME, Meade R, Maynard GD, Thurkauf A, Chien DS, Hutchison AJ, Krause JE. Identification and characterization of NDT 9513727 [N,N-bis(1,3-benzodioxol-5-ylmethyl)-1-butyl-2,4-diphenyl-1H-imidazole-5-methanam ine], a novel, orally bioavailable C5a receptor inverse agonist. J Pharmacol Exp Ther. 2008 Dec;327(3):898-909. doi: 10.1124/jpet.108.141572. Epub 2008 Aug 27. PubMed PMID: 18753409. Kelly JM, Amor-Coarasa A, Nikolopoulou A, Wüstemann T, Barelli P, Kim D, Williams C Jr, Zheng X, Bi C, Hu B, Warren JD, Hage DS, DiMagno SG, Babich JW. Dual-Target Binding Ligands with Modulated Pharmacokinetics for Endoradiotherapy of Prostate Cancer. J Nucl Med. 2017 Sep;58(9):1442-1449. doi: 10.2967/jnumed.116.188722. Epub 2017 Apr 27. PubMed PMID: 28450562.

纯度：≥98%

CAS：949575-22-8